Akebia Ther (AKBA) revenue breakdown

Healthcare · Drug Manufacturers - Specialty & Generic · Market cap $193M

By product, Product revenue, net is the largest at 96% of fiscal 2025 revenue, growing 65% a year over 7 years.

Revenue by product

Fiscal years, as Akebia Ther reports them in its 10-K filings; fiscal 2025 total $236M.

Products20182019202020212022202320242025Share
Product revenue, net$7M$111M$129M$142M$177M$170M$152M$227M 96%
License, collaboration and other revenue$201M$224M$166M$71M$116M$24M$8M$9M 4%
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AKBA.
Open AKBA in Investingly

Questions

Where does Akebia Ther make its money?

In fiscal 2025, by product: Product revenue, net $227M, License, collaboration and other revenue $9M.

From Akebia Ther's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.